Physiometrix, Inc., Announces FDA Clearance Of Its Next Generation Monitor

Physiometrix, Inc., Announces FDA Clearance Of Its Next Generation Monitor 


NO. BILLERICA, Mass., Feb. 10  /PRNewswire-FirstCall/ -- Physiometrix, Inc. 
announced today that it has received clearance from the Food and Drug
Administration (FDA) for commercial distribution of its PSA 5000 next generation
monitor. The PSA 5000 is a new state of the art monitor that is more powerful,
cost effective and ergonomic than it's predecessor the PSA 4000. The company
anticipates launch of the product through its exclusive distribution partner,
Baxter Healthcare, later this year.

"This very rapid response by FDA reflects positively on the strength of our
regulatory team at Physiometrix and we are most enthusiastic about the potential
of our new next generation monitor," said John A. Williams, president and chief
executive officer. "This innovative new platform allows level of consciousness
monitoring to be done conveniently anywhere in the hospital setting, including
the operating room and intensive care unit. Feedback from clinicians has been
superlative and we eagerly await the launch with our partners at Baxter
Healthcare," Williams concluded.

Designed for use by anesthesiologists, the PSA 4000 / 5000 is a device that
enables an anesthesiologist to monitor and manage a patient's level of
consciousness under anesthesia in the operating room and intensive care unit.
The PSA 4000 / 5000 has the potential to enhance patient care and improve
recovery times in hospitals across the U.S. and around the world.

Physiometrix, Inc. designs, manufactures and markets noninvasive medical
products -- based on novel gel materials, sophisticated signal-processing
electronics technologies, and proprietary software -- for use in anesthesia-
monitoring during surgical procedures.

Safe Harbor Statement

Statements in this press release regarding Physiometrix's growth and future
business results of the Company are "forward-looking" statements as defined in
the Private Securities Litigation Reform Act of 1995.  Such statements are based
upon management's current expectations and are subject to a number of factors
and uncertainties.  Information contained in these forward-looking statements is
inherently uncertain, and actual performance and results may differ materially
due to many important factors.  Such factors that could cause actual results to
differ materially from any forward-looking statements made by the Company
include, among others, revenue estimates, dependence on existing and future
products, uncertainty of market acceptance, intense competition, partnership
agreements, and government regulations, especially regulatory approvals.  Other
relevant risks are described in the Company's Form 10-K filed March 28, 2003 and
Form 10Q dated November 14, 2003, with the SEC.

  CONTACT:
   Daniel W. Muehl, CFO
   Physiometrix Inc.
   978-670-2422


DATASOURCE: Physiometrix, Inc.



CONTACT:  Daniel W. Muehl, CFO, Physiometrix Inc., [phone] 



Web site:  http://physiometrix.com/

Copyright